serine and Sarcoma
serine has been researched along with Sarcoma in 4 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2) every 3 weeks." | 9.20 | Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. ( Babovic, N; Blay, JY; Bompas, E; Chawla, SP; Cohen, P; Cupissol, D; Demetri, GD; Franke, FA; Isambert, N; Italiano, A; Le-Guennec, S; López-Pousa, A; Pápai, Z; Penel, N; Saâda-Bouzid, E; Santoro, A; Staddon, AP; Tolcher, AW, 2015) |
| " Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2) every 3 weeks." | 5.20 | Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. ( Babovic, N; Blay, JY; Bompas, E; Chawla, SP; Cohen, P; Cupissol, D; Demetri, GD; Franke, FA; Isambert, N; Italiano, A; Le-Guennec, S; López-Pousa, A; Pápai, Z; Penel, N; Saâda-Bouzid, E; Santoro, A; Staddon, AP; Tolcher, AW, 2015) |
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Wang, Y | 1 |
| Ilyas, FZ | 1 |
| Kheradmandi, M | 1 |
| Tsilimigras, DI | 1 |
| Grignol, VP | 1 |
| Contreras, C | 1 |
| Tsichlis, PN | 1 |
| Pollock, RE | 1 |
| Beane, JD | 1 |
| Blay, JY | 1 |
| Pápai, Z | 1 |
| Tolcher, AW | 1 |
| Italiano, A | 1 |
| Cupissol, D | 1 |
| López-Pousa, A | 1 |
| Chawla, SP | 1 |
| Bompas, E | 1 |
| Babovic, N | 1 |
| Penel, N | 1 |
| Isambert, N | 1 |
| Staddon, AP | 1 |
| Saâda-Bouzid, E | 1 |
| Santoro, A | 1 |
| Franke, FA | 1 |
| Cohen, P | 1 |
| Le-Guennec, S | 1 |
| Demetri, GD | 1 |
| Quek, R | 1 |
| Hori, K | 1 |
| Saito, S | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemother[NCT00699517] | Phase 3 | 355 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
1 review available for serine and Sarcoma
| Article | Year |
|---|---|
The Role of AKT in Soft Tissue Sarcoma: Review and Insights.
Topics: Humans; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; S | 2022 |
Trials
1 trial available for serine and Sarcoma
| Article | Year |
|---|---|
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Cisplatin; Disease-Free Survival; Double-Blind Metho | 2015 |
Other Studies
2 other studies available for serine and Sarcoma
| Article | Year |
|---|---|
Tumour vascular-disrupting agents in soft-tissue sarcoma.
Topics: Cisplatin; Female; Humans; Male; Sarcoma; Serine | 2015 |
Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700).
Topics: Animals; Antineoplastic Agents, Phytogenic; Catecholamines; Epinephrine; Necrosis; Neoplasms, Experi | 2004 |